Bin Liu

Senior Manager, Gene Therapy, In vivo Pharmacology, Preclinical drug development program lead, AAV payload engineering

Bin Liu is currently a Senior Manager at Vertex Pharmaceuticals, specializing in gene therapy and preclinical drug development. He has been in this role since June 2023 and is based in the Greater Boston area. His responsibilities include leading programs focused on AAV (adeno-associated virus) payload engineering and in vivo pharmacology.1 2

Educational Background

Postdoctoral Fellowship at Harvard Medical School (2008 - 2012), focusing on Alzheimer's Disease, Treatment, and Immunotherapy.
Ph.D. from the Institute of Materia Medica, CAMS & PUMC (2003 - 2008), specializing in Parkinson's Disease, Proteomics, and Biomarkers.
Bachelor of Science in Pharmaceutical Science from Peking University (1999 - 2003).

Professional Experience

Before joining Vertex, Bin Liu held several significant positions:

Associate Scientific Director at Biogen (May 2022 - April 2023), where he led cross-functional teams in gene therapy projects.
Principal Scientist and Senior Scientist roles at Biogen, focusing on gene therapy technologies and project management.
Senior Scientist at Voyager Therapeutics, where he led IND-enabling studies for AAV-based therapies targeting Huntington's disease.1 2

Liu's extensive experience in the biotechnology sector is complemented by his strong academic foundation, making him a key contributor to advancements in gene therapy.